Merck COVID-19 pill linked to virus mutations – study (NYSE:MRK)

Summary by Ground News

Lagevrio, the FDA-authorized oral COVID-19 therapy, leads to new mutations in the virus, according to a new study. The researchers in the U.S. and U.K. collaborated with those in the Francis Crick Institute, Imperial College, and the University of Liverpool.

Published 4 months ago

News Articles

More
Filters

All

Left

Center

Right

South China Morning Post

Merck’s Covid-19 drug linked to new virus mutations, study says

Merck & Co’s Covid-19 pill is giving rise to new mutations of the virus in some patients, according to a study that underscores the risk of trying to intentionally alter the pathogen’s genetic code.

4 months ago·Hong Kong

Read Full Article

Bloomberg

Merck Covid Drug Linked to New Virus Mutations, Study Says - BNN Bloomberg

Merck & Co.’s Covid-19 pill is giving rise to new mutations of the virus in some patients, according to a study that underscores the risk of trying to intentionally alter the pathogen’s genetic code.

4 months ago·United States

Read Full Article

Seeking Alpha

Merck COVID-19 pill linked to virus mutations – study (NYSE:MRK)

Lagevrio, the oral COVID-19 therapy developed by Merck (MRK) Ridgeback Biotherapeutics, leads to new mutations in the virus with the potential for further spread. Read the full story here.

4 months ago·United States

Read Full Article